Conference on the Transdisciplinary Frontiers of Psychedelic Studies
Panels and Topics:
Basic and Translational Science (Early Morning): Present the latest evidence on psilocybin, ketamine, and ibogaine, grounding the Forum in rigorous science and clinical practice.
Clinical Models (Morning): Share experiences of ibogaine and psychedelic care delivery across different systems and countries.
Educational Demonstration (Late Morning): A theatrical portrayal of the patient journey through psychedelic therapy, making the science tangible for policymakers.
Legal Frameworks (Midday): Examine lessons from Oregon, Colorado, and New Jersey on how to regulate psychedelic and cannabis access.
Public Sector Roadmaps (Early Afternoon): Map strategies for responsibly integrating psychedelics and cannabis into municipal and state health systems.
Manufacturing and Supply (Afternoon): Explore how GMP manufacturing and pharmaceutical standards underpin safe, scalable psychedelic therapies.
Economics and Data (Afternoon): Highlight financial models, reimbursement structures, and usage data that support policy and coverage decisions.
Patient Panel (Late Afternoon): Lived experiences of treatment highlight both promise and ongoing barriers to access.
Keynote Interview (5:0 PM): Bryan Hubbard outlines the roadmap behind Texas’s $50M ibogaine rollout, offering a model for scalable adoption.
Our mission is to create an inspiring and inclusive space for psychedelic education, scholarship, and community. This conference cultivates a setting of diverse experts to facilitate meaningful discussion, foster ideas, and expand understanding. Together, we will consciously and creatively advance the field of psychedelics for the greater good of society.
Our Mission
View Past Philadelic Conferences:
Tribute to Norma Lotsof
The Penn Psychedelics Collaborative honors Norma Lotsof, whose lifelong dedication helped bring ibogaine from the margins of underground discovery into the modern dialogue on addiction treatment and psychedelic medicine. Together with her late husband, Howard Lotsof, Norma’s advocacy, compassion, and perseverance laid the foundation for much of the ibogaine research and practice that exists today. Norma now faces significant medical and financial challenges, and the global ibogaine community has come together to support her through this GoFundMe campaign. We invite our community to join in honoring her extraordinary contributions and helping ensure she receives the care and dignity she deserves.
Tribute to Nolan R. Williams, MD
The Penn Psychedelics Collaborative honors Nolan R. Williams, MD, was a pioneering psychiatrist and neuroscientist whose work transformed how we think about treating severe mood disorders, particularly through his leadership in ibogaine research. As Director of the Stanford Brain Stimulation Lab, he helped design and study carefully monitored ibogaine protocols for veterans and others living with depression, PTSD, traumatic brain injury, and substance use disorders, documenting rapid, sustained reductions in mood and trauma symptoms after a single treatment. By pairing ibogaine with sophisticated brain imaging and electrophysiology, he began to map how this powerful medicine reshapes neural circuits involved in mood, opening new paths toward safer, more precise therapies. Nolan’s work offered hope to people who had exhausted conventional options, and his blend of scientific rigor, clinical courage, and deep compassion continues to guide the emerging field of ibogaine assisted care for mood and trauma related disorders.
The PhilaDelic Conference is an initiative of the Penn Psychedelics Collaborative at the University of Pennsylvania.
